Index

In this index, boxes are indicated by box; tables are indicated by t; figures are indicated by fig.

Abas, M., 61
acceptance and commitment therapy (ACT), 127–128, 132–133, 135
Access to Allied Psychological Services (ATAPS), 376, 381

© in this web service Cambridge University Press

www.cambridge.org
definitions and characteristics, 252
detoxification, 260–261
drinking histories and, 255–256
hallucinations in, 252
health effects of, 253
medication prescribed for, 260, 262
mental illness classifications and, 70, 234
NICE guidelines on, 261
prevalence of, 18
referrals to health services for, 260
screening for, 254
withdrawal from, 254, 258
alcohol use problems overview, 251, 263
alcohol trends and, 252–253
Alcohol Use Disorders Identification Test for, 254
Alcohols Anonymous and, 256
anxiety caused by, 128
AUDIT for, 254
barriers to brief intervention in, 263
barriers to PCMH intervention for, 259
brief intervention for, 254, 256
CAGE questionnaire on, 255
comorbidity and, 247, 260
in case study, 258
cost savings for, 364
definitions and characteristics, 251–252
delirium caused by, 156
detoxification, 256
diagnosis of, in PCMH, 253
drinking histories and, 255–256
drug overdose involving, 242
Fast Alcohol Screening Test for, 255
FRAME intervention for, 256
GBD report on, 253
as a global issue, 253
263
among GPs, 481
harm caused by, 238, 253, 256
IBA intervention for, 253–254
interventions in, 360
key points of, 263
life expectancy reduced by, 238
management of, 253, 256
maternal, 156
mental illness classifications and, 70, 234
mortality from, 253
ODHIN trials in, 260
parental, 238
PCMH implementation of IBA, 260
PCMH screening opportunities for, 254
during pregnancy, 358
prevalence of, 354
prevention of, 359
psychological therapies for, 422
recording of, 259
RTCs for, 258
screening for, 266
SDGs for, 59
vs. sensible alcohol use, 251
as suicide risk factor, 112
support groups for, 262
talking therapies for, 257
in young people, 355
Alderson, S.L., 42
Alberty, Henry, vii, 480
Allardyce, M.C., 41
anorexia nervosa, 78–79
hyperprolactinaemia
as suicide risk factor, 473–474
withdrawal from, 230
antipsychotic medications for anxiety, 92, 95–96
in PTSD, 193
for prisoners, 33
for bulimia nervose, 25
for children and adolescents, 206
depression and, 93, 94–96
for dysthymia, 88
effectiveness of, 20
eating disorders
Alzheimer’s disease. See older people (dementia in)
Alzheimer’s Society, 16, 167, 168
AMP (Improving Access to Mental Health in Primary Care) programme, 390
Angermeyer, M.C., 41
Anne Hallucinations, 286
and, 286
in emergencies, 229
hyperprolactinaemia
and, 290
lithium and, 293
Index489

Cambridge University Press
978-1-911-62302-1 — Primary Care Mental Health
Edited by Linda Gask, Tony Kendrick, Robert Peveler, Carolyn A. Chew-Graham
Index
More Information
antipsychotic (cont.)
low-dose, 220–221
osteoporosis and, 291
sexual problems and, 290
side effects of, 218
vs. untreated psychosis, 215
weight gain from, 289
anxiety. See also collaborative care; generalised anxiety disorder; panic disorder; prison populations and offenders; sexual problems; social anxiety disorder (social phobia); stepped care overview, 125–135
access to PCMH for, 386
in adjustment disorder, 88–89
antidepressant medication for, 193
in asylum seekers/refugees, 311, 312, 316, 318
benzodiazepine use and, 244
burdens of, 373, 401
comorbidity in, 74–75
definitions and characteristics, 125
depression combined with, 75/96.1, 87, 126, 127, 135, 159, 161
drug misuse and, 240, 246–247
epidemiology and classification of, 125–126
in families of drug users, 247–248
among GPs, 480, 481
health anxiety/illness disorder, 131
helplessness vs. hopelessness in, 127
Hospital Anxiety and Depression Scale, 80
IAPT treatment for, 46
inventories and scales measuring, 129
key points of, 135/box
LTCs and, 175, 180
management of, 180, 376–377
mindfulness-based interventions for, 132–133
normal vs. abnormal, 125
PCMH treatment of, 3, 8, 12
prevalence of, 16, 125, 401
PROMs monitoring, 129
rates of, increasing, 25
Revised Child Anxiety and Depression Scale, 203–204
screening and case-finding of, 127
secondary care referrals for, 134
severity measurements of, 92
traditional healing and, 63
anxiety disorders. See also generalised anxiety disorder in acute mental health emergencies, 228
antennatal, 186–187
benzodiazepines for, 133–134
burdens of, 125–126
in case studies, 140–141
CBT for, 46–47
in children and adolescents, 191, 200–201, 203
cost savings for, 364
definitions and characteristics, 128/9.2–129/9.2
depression combined with, 135/box
detection of, 19
diagnosis of, 127–131, 135/box
eating disorders and, 268
first, second and third line medication for, 133/9.3
functional impairment resulting from, 132–134
GAD-7 score for, 80
IAPT treatment for, 46
interventions for, 132–134
key points of, 135/box
in LAMI countries, 63
management of, 131–134, 376–377
medication prescribed for, 133–134, 135/box
NICE guidelines on, 131–134
perinatal, 186–187
physical symptoms in, 125, 127–131, 128–129/9.2, 135/box
presentations in PCMH, 127–129
prevalence of, 126/9.1
psychological therapies for, 135/box, 422/box29.1
recognition of, 132
screening and case-finding of, 135/box
secondary care referrals for, 135/box
starting ages of, 354/25.2
substance misuse and, 75–76
treatment-refractory anxiety disorders, 134
triggers of, 128–129/9.2
Arroll, Bruce, vii, 125
Asia, 55, 57, 63, 74–75, 301.
See also ethnic minorities;
South Asian minorities;
South East Asia
Asian ethnic minorities, 301, 303–304, 386.
See also South Asian minorities
asylum seekers and refugees. See also ethnic minorities
overview, 311–322
access to mental health care for, 322, 390
anxiety in, 311, 312–313, 316, 318
assessment of psychological problems in, 312–313
building trust with, 314
in case studies, 312, 316, 319
children as, 318, 320
CMHT services for, 321
cost savings for, 364
IAPT treatment for, 46
interventions for, 132–134
key points of, 135/box
in LAMI countries, 63
medical and classification of, 311
in exile, 311, 312, 314, 317–318, 322/box
guidelines for practitioners serving, 322
interpreters for, 314–315, 318
issues common to, 315–318
management issues for, 318–320
medication prescription for, 320, 322/box
older people as, 318
political issues among, 313, 314, 318–319
poverty among, 311, 313, 322/box

© in this web service Cambridge University Press

www.cambridge.org
oppositional defiant disorder, 201–202, 203, 206t
panic disorder among, 129–130
PCMH and, 354t
phobias among, 130
physical health problems and, 200, 203
physical illness and, 202
policy and future directions for, 209
presentations of, 200–203
prevalence of, 200, 354t
psychological interventions in, 207
psychotic disorders among, 220
questionnaire measurements of, 203–204
referrals to health services for, 202, 204, 205t
self-harm among, 114, 201, 355t
self-help therapies for, 204–205
severe impairment disorders, 200
smoking and, 354t, 355t
stepped care for, 209–210
suicide and, 114, 201
child mortality, 57, 58t
Chile, 182, 20, 404
China, 182, 59
Chronic Care Model, 178
chronic fatigue syndrome, 19, 138, 140–141
Cipriani, A., 464–465
City and Hackney Clinical Commissioning Group, 45
Clinical Commissioning Groups (CCGs), 49, 195, 349
CMHT (Community Mental Health Team), 217, 247, 393–394, 395, 396
Cochrane reviews (Cochrane Database of Systematic Reviews), 105–106, 191, 194, 207, 338
cognitive analytic therapy (CAT), 348, 432, 478
cognitive behavioural therapy (CBT). See also mindfulness-based therapy; talking therapies for anxiety disorders, 46–47
behavioural activation in,
424box
brief psychological interventions in,
424box
for childhood depression, 208
for depression, 20, 94, 96–97, 98t
for fatigue issues, 446
for GAD, 132–133
high intensity CBT, 406–407
in the IAPT programme, 376, 389
intervention economics of,
362t
limitations of, 26–27,
34box
mindfulness-based therapy in,
432–433
for MUS, 146
as new field in PCMH, 32, 36box
for panic disorder, 132–133
patients’ preferences for, 30
for perinatal mental health problems, 191
for postnatal depression, 192box
in psychological therapy referral model, 403
for psychotic disorders, 220–221
self-help therapies and, 93, 424, 428–429
for sexual problems, 335–336
shortage in practitioners of, 46
stepped care and, 421fig
via technology, 391
third wave of, 96–97,
132–133
in treatment decisions,
473–474, 475
as treatment model, 716.1
Collie, Frances, 420–434
Collin-King, Aly, vii–viii, 103–119
collaborative care overview, 401–413
access to PCMH care improved by, 390, 391–392
aims and principles of, 404, 413
in AMP project, 390
for depression, 6, 97, 103
for SMI patients, 397, 405–406
for LTCs, 179
future developments for, 413
for common mental health/ problems, 178–179
consultation-liaison model as precursor to, 403–404
for depression, 6, 97, 404–405
effectiveness of, 404–405, 413
future developments for, 413
IT resources in, 405
key points of, 413
for LTCs, 179
multiple-professional communication enhanced in, 405
for MUS, 146
nurses’ involvement in, 379
PCMH education and, 379
PCMH teams and, 373
in the primary care/specialist interface, 393, 396
psychological therapy components of, 405
service delivery issues in, 405, 413
for SM patients, 397, 405–406
more information
collaborative care (cont.)
for South Asian women, 390
in suicide prevention, 115, 119–120
telephone-based, 404, 412–413
trial treatment models, 30
trials of, 404
Collinson, Sue, vii–viii, 39–49
Colombia, 61
common mental health problems. See also anxiety; 
headings under depression overview, 401–413
access to care for, 386
collaborative care models for, 397
IAPT programme and, 376, 388–389
identification of, 376–377
intervention gaps in, 361–364
in LAMI countries, 61–62
LTGs and, 175, 177–180
management of, 376–377, 401–402
models of service for, 375, 402–403
monitoring of, 92, 129, 177–180
NICE guidelines on, 387–388 box27.1
PCMH teams’ roles in care of, 376–378, 381 box
perinatal, 195, 196 box
poverty and, 63–64
prevalence of, 16, 17, 182.1, 200, 379, 403
psychological therapies for, 406–407
remotely provided therapy for, 391
screening for, 127
social views of, evolving, 24
socioeconomic status and, 357, 373–374
sociological factors in, 462
talking therapies for, 25
treatment decisions regarding, 476–477
 treatment not received for, 396–397
Community Mental Health Team (CMHT) model, 217, 247, 393–394, 395, 396
comorbidity. See also morbidity; 
multimorbidity alcohol use problems and, 247, 260, 261 box18.5
in anxiety, 126
in child and adolescent mental health problems, 203
depression and, 92, 159
in depression assessment and management, 449–450 box30.2
diagnostic systems and, 82 box
drug use disorders and, 247
in eating disorders, 267, 269–270
LTGs and, 175, 177
management of, 177–178
mental health problems presenting with, 4, 73, 74–76
MUS and, 143
National Comorbidity Survey, 14
nurse monitoring of, 380
in older people, 162 box11.5
PCMH teams addressing, 373–374
PICO treatment and, 476 box32.1
in prisoners/offenders, 343
RCTs and, 475
research including patients with, 478
schizophrenia and, 278 box20.1
in sexual problems, 331, 336
in South Asian ethnic minorities, 301
surveys on, 14
computer-based cognitive-based therapy (cCBT), 34 box3.1, 35, 46, 94, 97, 391, 397 box, 397
consultation-liaison model, 375, 396, 403–404
coronary heart disease, 41, 97, 176–177 box12.1, 179, 392–393
Coughtrey, Anna, vii–viii, 200–209
Coupe, N., 467
Coventry, Peter, vii–viii, 175, 181 box12.3, 401–413
CQC’s (Care Quality Commissions), 49
Creswell, J., 466–467
Czech Republic, 375
DALYs (disability adjusted life years), 16, 17, 89–90. See also burdens of specific mental disorders
Day, Ed, vii–viii
de Shazer, Steve, 119
Defeat Depression in suicidal thought in psychosis detection, 216
in postpartum psychosis, 187
in psychosis detection, 216
in suicidal thought examination, 112 box8.3
dementia. See also older people (dementia in)
burdens of, 17
disabling nature of, 17
in LAMI countries, 20, 163–164
PCMH treatment of, 14
secondary care treatment of, 12
specialist care for, 19
Denmark, 70–72, 374
deprescribing of medications, 47
depression. See also antidepressant medications; child and adolescent mental health problems; older people (depression in); perinatal mental health problems (postnatal depression); PHQs (Patient Health Questionnaires); prison
populations and offenders; sexual problems
(depression (general)
overview, 87–98
access to PCMH treatment
of, 97, 98box
adjustment disorder and, 88–89
alcohol use problems and, 240
Alliance Against
Depression, 6
Alliance Against Depression
programme, 6
anxiety combined with,
759/6, 1, 87, 126, 127, 135, 159, 161
Beck Depression Inventory
for, 80, 92, 93/7, 1, 129
behavioural activation
for, 431
and bereavement, 87
Beyond Blue project, 6
bipolar disorder and, 92
burdens of, 373, 401
CBT treatment for, 20
chronic and recurrent, 40,
42–43, 74, 96box7, 3,
162box11, 5, 379, 381box,
433, 474, 477
collaborative care treatment
models, 6
comorbidity and, 74–75, 92
continuum of severity of, 15
contemporary heart disease and,
97, 379
cost savings for, 364
criteria of, 70, 72/62
Cultural expressions of,
29–30, 188
DALYs lost to, 89–90
Defeat Depression
Campaign, 6
definitions and
characteristics, 87–89
detection of, 91–97
diabetes and, 286, 379
diagnosis of, 15, 17–18, 42,
72/6, 72, 89, 244, 304,
464–465
drug misuse and, 246–247
epidemic of, 98
epidemiology of, 74, 89–90
in ethnic minorities, 301,
303–304
external sources of, 40–41
fatigue and, 19
focus on, renewed, 6
functional impairment
and, 81
among GPs, 480, 481, 482, 484
Hampshire Depression
Study, 462
Hospital Anxiety and
Depression Scale, 80
IAPT treatment for, 46
intervention economics of,
362/25.6
interventions for, 359,
362/25.6
Inventories to Diagnose
Depression, 80
key points of, 98box
life expectancy and, 279/20.2
LTCS and, 91, 92, 175–176,
177–179, 180, 181box, 379
management of, 91–97,
376–377
medical education and, 446
medication comparison
studies for, 468
mindfulness-based
interventions for, 96–97
morbidity and, 74
multimorbidity and,
175–176
new approaches to treatment
of, 26
NICE guidelines on, 91
observational studies of, 462
Overcoming Depression
treatment programme,
93–94
patients’ descriptions of,
40–41
PC vs. specialist interests
in, 447
PCMH assessment and
management of,
449–450box30.2
in PCMH attenders, 19,
45–46
PCMH research priorities
for, 97–98
PCMH treatment of, 8, 26,
39, 42–43
perinatal depression, 359
physical illness and, 90,
353–356
physical symptoms of, 41
poverty and, 286
prevalence of, 16,
354t25.1, 401
in primary- vs. secondary-
care patients, 474, 475
PROMs monitoring, 92
psychological therapies for,
98box, 422box29.1
questionnaires on, 93t1.1,
98box
rates of, increasing, 16, 17, 25
recall bias and, 462
recognition of, 90, 91–93,
98box, 181box
referrals of patients with, 474
research into diagnosis
of, 462
Revised Child Anxiety
and Depression Scale, 203–204
risk factors for, 90box7.2, 90
secondary care for, 96box7.3
self-help therapies and,
406–407
severity measurements and,
90, 92
social stressors causing, 90
vs. somatic symptoms, 90
stepped-care
recommendations for, 8,
91
stigma removed from, 26
stress causing, 40
suicide and, 104, 118
suicide prevention and, 359
terminologies describing, 9
timing of treatment of, 89
traditional healing and, 63
trigger symptoms for, 87–88
women’s help-seeking
responses in, 73
years lived with, 401
YLDs caused by, 89
depression (major)
access to mental health care
lacking for, 393–394
antidepressant treatment
for, 95
bereavement and, 87, 159
in case studies, 473–475,
476–477, 478
detection of, 91
drug treatment aversion
and, 478
in families of drug users,
247–248
guideline recommendations
for, 473–474
life expectancy reduced by,
355t25.4
depression (major) (cont.)
management of, 91
in older people, 162
vs. other depression intensity levels, 89
PHQ-9 assessment for, 88
PICO treatment approach to, 473–475, 478
prevalence of, 17
questionnaires on, 93
risk factors for, 81
symptoms of, 88
systematic reviews of, 464–465
treatment decisions regarding, 473–475, 478
depression (mild to moderate) access to PCMH for, 386
antidepressants not recommended for, 93
bibilotherapy for, 93–94
brief psychological therapies for, 94
diagnosis/recognition of, 88
digital mental health interventions for, 94
disabling nature of, 17
drug misuse and, 240
internet-based CBT for, 93–94
persistent, 93–94
PICO treatment approach to, 476–477
questionnaires on, 93
recognition of, 90
self-help therapies for, 93–94, 98
social difficulties of, 476–477
depression (minor), 88, 89, 93
depression (mild to severe), 94–96, 97
depression(postnatal/postpartum). See perinatal mental health problems (postnatal depression)
depression (sub-syndromal), 87, 158–159
depression (sub-threshold) adjustment disorder and, 88
antidepressants not recommended for, 93
bibilotherapy for, 93–94
brief psychological therapies for, 94
detection of, 91
diagnosis of, 88
digital mental health interventions for, 94
internet-based CBT for, 93–94
management of, 91
vs. other depression intensity levels, 89
persistent, 93–94
treatments for, 93
Depression Attitude Questionnaire (DAQ), 378, 447
Depression Awareness, Recognition and Treatment Programme (DART), 6
DeRubeis, R.J., 409
Di Bona, L., 411
Di Cernenti, C.C., 425–426
Disability Assessment Schedule (DART), 6
Disability Assessment Schedule (WHO-DAS), 81
disability-adjusted life years. See DALYs disruptive behaviour disorders, 200–202, 207, 209–210
Dowell, R., 98
Dowrick, Christopher, viii–viii, 70–82, 138–148, 467
drug dependence cannabis use and, 244
definitions and characteristics, 238, 240–241
in drug misuse spectrum, 236
early age substance misuse and, 236–237
harm caused by, 238
heroine in, 242, 246, 343
interventions for, 241
242–243, 244, 248
mental health services’ involvement in, 70
methadone treatment for, 242, 246, 348, 461
MUS management vs., 146
opioid substitution treatment for, 242, 248

morbidity problems in, 74–76
as PCMH specific, 73, 76–77
personality disorders and, 72
physical, mental and social problems present in, 73–74
recommendations for, 82
screening tools and, 80
severity measurements and, 80
specialist-primary care communication in, 82
specialists’ recognition of, 73
subthreshold disorders in, 76
syptomology fluctuations in, 74
systems of, in PCMH, 76–77, 82
treatment models and, 71
validity of, 74–76
varieties of, increasing, 70–72

Dowrick, Christopher, viii–viii, 70–82, 138–148, 467
drug dependence cannabis use and, 244
definitions and characteristics, 238, 240–241
in drug misuse spectrum, 236
early age substance misuse and, 236–237
harm caused by, 238
heroine in, 242, 246, 343, 344
interventions for, 241
242–243, 244, 248
mental health services’ involvement in, 70
methadone treatment for, 242, 246, 348, 461
MUS management vs., 146
opioid substitution treatment for, 242, 248

© in this web service Cambridge University Press www.cambridge.org
opioids in, 242, 245
pain management and,
245–246, 248
prescription drugs and,
32–33
withdrawal from,
254–box18.2
drug use disorders. See also
substance misuse/abuse
overview, 236–248
acutely disturbed behaviour
caused by, 227–box16.1
anxiety caused by, 128
assessment of, 236, 241,
248
benzodiazepines in, 244–245
cannabis in, 215, 216, 236,
237/17.1, 239/17.2, 240,
243–244, 248
cardiovascular disease
and, 243
in case study, 241
CMHT services for, 247
cocaine in, 236, 237/17.1,
238
comorbidity and, 247
definitions and
characteristics, 237
depression caused by, 240
detoxification and,
244–245, 246
diagnosis of, 238
drugs promoting abstinence
and, 260–261
in DSM-5, 238
ecstasy in, 227–box16.1, 236,
237/17.1, 243
emotional disorders and,
355–box25.3
family members affected by,
247–248
among GPs, 481
GPs' roles in treating, 236,
241, 248
hallucinogens in, 239/17.2,
243, 244
heroin in, 238, 241, 242,
246, 344–box24.1
incarceration for,
344–box24.1
interventions for, 241,
242–243, 244, 248
intravenous injections in,
238–241, 239/17.2,
242, 243
key points of, 248
life expectancy reduced by,
355–box25.4, 360
maternal, 237
mental health issues and,
246–247
mortality from, 240, 245
novel psychoactive
substances in, 244
opioids in, 237, 239/17.2,
242, 244, 245–246, 248
overdosing in, 242
parental, 238, 262
physical consequences of,
238–240, 239/17.2, 248
poverty and, 240
during pregnancy, 358
presentation and treatment
options, 240–241
prevalence of, 354–box25.1
psychological consequences
of, 240, 248
psychological therapies for,
422–box29.1
rates of, 236–237
risk factors for, 237–238,
248
sedatives in, 239/17.2
social consequences of, 240,
246–247, 248
as a spectrum, 236, 248
stimulants in, 239/17.2, 240,
243, 244, 248
suicide and, 112–box8.3,
233–234
users’ profiles, 236, 237/17.1,
240–241
Druss, B.G., 406
DSM-5 (Diagnostic and
Statistical Manual of
Mental Disorders)
cross-applications of, 76
depression-related updates
to, 87
diagnostic criteria for major
depression in, 726.2
as mental health classification
system, 76–77
MUS and, 138–139
new diagnostic
classifications in, 75
PCMH adaptations lacking
in, 79
in perinatal settings, 186
sexual problems in, 328, 336
similarities with ICD-10, 15
somatic disorders in, 131
substrate use disorder
in, 238
subthreshold disorders
and, 76
as US diagnostic/
classification system,
70–72
DSM-IV-PC (Diagnostic and
Statistical Manual of
Mental Disorders), 79, 336
Dunham, W., 215
dysthymia, 88, 477
eating disorders. See also
anorexia nervosa; binge
eating; bulimia nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
distress caused by, 267–271
east eating; bulimia nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
267–268
idiopathic; eating; bulimia
nervosa
overview, 267–273
barriers to intervention for,
269–270, 273–274
in case studies, 271–272
comorbidity and, 268,
269–270, 273–274
definitions and characteristics,
eating disorders (cont.)
prevalence of, 354t25.1
questionnaires on, 270–271
referrals to health services for, 271–272/19.2, 273
risk assessment of, 273
rumination disorders, 267–268/19.1
SCOFF questionnaire on, 270–271
screening for, 270–271
stages of, 268–269, 273
stimulants and, 239/t17.2
in women, 268–269, 273–274/boxu
in young people, 268–269, 270, 273–274/boxu
eczema (MDMA). See drug use disorders; psychotic disorders
ED. See eating disorders
education and training model, 402
education in mental health. See teaching and learning about mental health
Egypt, 61
Ekers, David, vii–viii, 420–434
emergencies in primary care overview, 226–234
acute confusional states as, 227–228
acutely disturbed behaviour as, 226–230
antidepressant withdrawal and, 230
benzodiazepine withdrawal and, 230
in case study, 226
comportment of health professionals in, 229
compulsory hospitalization and, 234
consultation approaches to, 227, 228–229
drug and substance misuse causing, 227/box16.1, 227, 234/box
dystonias as, 229
iatrogenic states in, 229–230
key points of, 234/box
lithium toxicity and, 230
management of mental health problems, 229
medication and, 228, 229
mental health problems as, 227/box16.1, 227, 228–229, 234/box
neuroleptic malignant syndrome as, 229–230
non-psychotic mental health problems and, 228
physical causes of mental health problems in, 227/box16.1, 227–228, 234/box
psychosis in, 228, 229
referrals to health services in, 229, 233–234
serotonin syndrome, 230
suicide risk in, 231–234, 234/box
empathy in CBT, 431
in counselling, 426–427
in depression assessment and management, 449–450/box30.2
diagnoses enhanced by, 17–18
toward drug abusers, 241, 247, 248/box
toward eating disorder patients, 270
in interviewing, 449–450/box30.2
lack of, in prisoners/offenders, 344/box24.1
medically unexplained symptoms and, 26
in motivational interviewing, 426/box29.3
NICE guidelines on, 40
as patient priority, 43, 49–50/box
toward refugees, 321
in suicide mitigation, 108–110
in therapeutic alliances, 344/box3.1
for torture victims, 315–316
epidemiology (general)
of anxiety, 125–126
of asylum seekers/refugees’ mental health problems, 311
of child and adolescent mental problems, 200
of dementia, 163–164
of depression, 74, 89–90, 158–159
of eating disorders, 268–269
epidemiology of, 164/t11.2
of perinatal health problems, 186–187
of psychotic disorders, 214–215
of sexual problems, 329–330
epidemiology of mental illness overview, 12, 21/box1.2
burden of psychiatric disorders and, 16–17
data collection in, 14
definitions and characteristics, 12, 21/box
international perspectives of, 20
key points of, 21/box
in LAMI countries, 20
mental illness within the community and, 15–16
MUS and, 19–20
pathways to psychiatric care and, 13–14
prevalence vs. need and, 20
psychiatric disorder assessment and definition in, 14–15
of psychiatric disorder in PCMH attenders, 17–19, 182.1
treatment availability and effectiveness rates and, 20
epilepsy, 61, 202, 261/box18.5
Estonia, 374, 375
ethnic minorities overview, 300–307
access to mental health care for, 304–305, 390
antidepressant medication less acceptable to, 303
barriers to PCMH intervention for, 303, 304–305, 305/box21.2, 307/box
in case studies, 302
cultural issues of, 300, 301, 303–305, 306
depression in, 29–30, 301, 303–304
in exile, 311, 312, 314, 317–318, 322/box
factors for mental health problems in, 301–305, 302/box21.1
health interventions for, 357
health services underused by, 303, 304–305
improvement in treatment outcomes for, 307
inverse care law and, 389
key points of PCMH for, 307
lack of treatment provision for, 301
lack of treatment-seeking among, 301
mental illness as stigma among, 303
mental illness rates among, 300–304
mental illness undetected in, 300
migration among, increasing, 300
multidimensional aspects of, 300
PCMH education and advocacy for, 307
PCMH issues in mental illness care for, 303–304
suicide in, 231–232
supernatural treatments sought by, 301, 303
treatments unacceptable to, 301
Eurobarometer study, 41–42, 48–49
Eurocommunication study, 46
European Union (EU), 127, 260, 374, 375
exercise as therapy alcohol use problems and, 257
anxiety and, 93, 425, 434
in case studies, 258, 271–272
475, 476–477
depression and, 425, 434
graded exercise therapy, 146–148, 446
LTCs and, 178
NICE guidelines on, 424–425
obesity and, 290
for older people, 161
perinatal mental health problems and, 194–195
in physiological therapies, 424
severe mental illness and, 291
sexual problems and, 333–334, 335, 337

exile. See asylum seekers and refugees
Expert Patient Programme, 48
exposure therapy, 132–133, 424
Faris, R.E.L, 215
Finland, 374, 375
Five Year Forward View mandate, 49
treatment model, 421–424, 423
428, 431, 433
Foley, D.L, 81
Forrester, Andrew, viii
France, 182
Fry, John, 1
Fuller, J.D., 393
GAD. See generalised anxiety disorder
Gask, Linda, viii, 1–9, 39–49,
70–82, 386–397, 401–413,
420–434, 459–469
GBD. See Global Burden of Disease (GBD) study
General Health Questionnaire (GHQ), 80
general practitioners and mental health overview, 480–486
Balint groups for, 485
barriers to care accessed by, 481–482
burn-out among, 480, 481, 482
confidence issues among, 484
treatment among, 480–486
medication for, 132
self-referral among, 484
younger age groups of, 480
general practitioners (GPs). See also Royal College of General Practitioners
core competencies for, 439–446, 440–445
emerging PCMH roles of, 1, 4–5, 39
majority of patients seen by, 393, 459
in PCMH teams, 9, 375
preferred over specialists, 25, 374
generalised anxiety disorder (GAD)
CBT for, 132–133
characteristics of, 128–129
as disabling, 125
as a disability, 125
first, second and third line medication for, 133
improvement lacking in, 132
LTCs and, 177
perinatal, 187
prevalence of, 16, 126
prognosis for, 126
psychological therapies for, 132–133
self-help therapies for, 132
triggers of, 128–129
Global Burden of Disease (GBD) study, 15–17, 89–90, 97, 253, 373.
See also burdens of specific mental disorders
Goldberg, David, viii, 7, 14, 17, 18t2.1, 21box, 439–456
Goodman, R., 203–204
Gourlay, D.L., 245
GPs. See general practitioners
Grand Challenges in Global Mental Health initiative, 55
Greece, 18t2.1, 374
Guinea Bissau, 61
Gunn, Jane, 2, 87–98
Gureje, Oye, viii, 54–64, 70–82
Gyani, A., 409
habitus, 24–25, 31
Haddad, Mark, viii, 373–381
hallucinations
in alcohol dependence, 252box18.1
in case studies, 171, 226
delirium and, 153, 154, 227–228
delusions and, 171
in Lewy-body disease, 165–166, 169
in psychoses, 187, 214–215, 216, 228
in psychosis, 226
suicidal thoughts and, 112box8.3
Hamilton, Fiona, viii, 251–263box18.6
Hammond, J., 466
Hart, Julian Tudor, 176
Hawton, K., 105–106
Health and Social Care Act (2012), 49, 361–362, 366box25.2
health anxiety/illness disorder, 131
Health for All by 2000 programme, 57, 58box5.2, 64
Healy, D., 33
Hearing Voices Network, 39–40
help-seeking behaviours and strategies
barriers to, 269–270
clinicians’ attitudes toward mental health issues and, 381box
gender issues in, 27–28, 29–30
GP’s preferred over specialists in, 374
material disadvantage reducing, 27, 304
patients’ individual experiences in, 8, 30–31
racial issues and, 28–30
somatic issues in, 29
suicide and, 114
treatment issues in, 31
by young people, 114
Henderson, M., 482
Heyman, Isobel, viii, 200–209
Hill, Jacqueline J., viii, 270, 401–413
Hispanic minorities, 303–304
HIV, 163box11.6, 239/17.2, 240, 241, 278box20.1, 292
HIV/AIDS, 57, 58box5.2, 58
Hodges, B., 447
holistic care
GP’s views of, 218
in LAMI countries, 64
mental illness and, 277–278, 295box, 295
NICE recommendations for, 134
as patient priority, 41, 46
PCMH advantages in, 4
PCMH integration as essential to, 9
PCMH teams providing, 172box, 222box
physical health problems and, 295
Royal College of General Practitioners and, 376, 440–445/30.1
as whole system
intervention, 180
Holt, Richard, viii, 277–295
Hospital Anxiety and Depression Scale (HADS), 80, 92, 93t7.1, 129, 177
Hull, Martyn, viii, 236–248
Human Development Index and Reports, 56box5.1
Hungary, 375
Huxley, P., 7, 14
hypochondriasis, 131, 138, 159, 161–162. See also medically unexplained symptoms; somatic issues
IAPT (Improving Access to Psychological Therapies) programme
access to mental health care improved by, 388–389, 394, 396–397, 397box
aims and features of, 14, 16, 26, 46, 388, 389
AMP programme in, 390
anxiety treatment in, 388, 389
attrition rates in, 388–389
in case study, 179box12.2
CBT in, 389
critiques of, 389
depression treatment in, 388, 389
as new role for PCMH, 376
patients’ preferences expressed in, 46
psychological therapies in, 420
psychological therapy referral model and, 402–403
specialist integration into, 381box
stepped care and, 407–409, 410
unavailability of, 389, 397box
iatrogenic conditions, 32, 33, 142, 144–145, 146, 147box10.1, 229–230
IBA (identification and brief advice), 253–254, 260
See also brief intervention
ICD-10 (International Statistical Classification of Diseases and Related Health Problems)
alcohol dependence criteria listed in, 252box18.1
limitations of, 76–77
as mental health classification system, 76–77
MUS and, 138–139
in perinatal settings, 186
subthreshold disorders
and, 76
as WHO diagnostic classification system, 70–72
ICD-10-PHC (simplified version of ICD-10), 70–72, 76–77
ICD-11 (ICD-10 revision)
adjustment disorder and, 88–89
cross-cultural validity of, 76
depression in, 70–72, 186
episode structure of, 79
<table>
<thead>
<tr>
<th>Index</th>
<th>501</th>
</tr>
</thead>
<tbody>
<tr>
<td>as mental health classification system, 75, 76–77</td>
<td>Khan, N., 40, 42</td>
</tr>
<tr>
<td>somatoform disorders and, 138–139</td>
<td>King, Alys Cole, 103–119</td>
</tr>
<tr>
<td>sub-threshold disorders and, 76</td>
<td>King, Michael, viii–ix, 327–338</td>
</tr>
<tr>
<td>ICD-11-PHC, 77box1.1</td>
<td>Kirkpatrick, D., 454</td>
</tr>
<tr>
<td>ICPC (International Classification of Primary Care), 726.2, 76–77, 138–139</td>
<td>Klinkman, Michael, viii–ix, 70–82</td>
</tr>
<tr>
<td>ICPC-2 classification system, 70–72, 76–79, 78–79box6.2</td>
<td>Klusmann, D., 41</td>
</tr>
<tr>
<td>identification and brief advice (IBA), 253–254, 260. See also brief intervention</td>
<td>Knapp, M., 118</td>
</tr>
<tr>
<td>improving access to health care. See access to mental health care</td>
<td>Korea, 375</td>
</tr>
<tr>
<td>Improving Access to Psychological Therapies programme. See IAPT programme</td>
<td>Kraepelin, Emil, 219</td>
</tr>
<tr>
<td>impulse control disorders, 201, 354</td>
<td>25.2</td>
</tr>
<tr>
<td>India, 182.1, 59, 61, 62, 63, 231–232box16.2</td>
<td>LAMI. See low and middle-income countries</td>
</tr>
<tr>
<td>Inventory to Diagnose Depression, 80</td>
<td>Latin America, 54, 55, 301</td>
</tr>
<tr>
<td>inverse care law, 176–177box12.1, 176, 389, 397, 462–463</td>
<td>Latvia, 375</td>
</tr>
<tr>
<td>Iran, 61</td>
<td>Lecrubier, P., 182.1</td>
</tr>
<tr>
<td>Iraq, 311</td>
<td>Lesser, A.L., 451</td>
</tr>
<tr>
<td>Isaac, Mohan, viii, 54–64</td>
<td>Lewis, Glyn, viii–ix, 12, 21box1.2</td>
</tr>
<tr>
<td>Italy, 182.1, 374</td>
<td>Leywarder body disease, 155–157, 163box116.6, 165–166, 169</td>
</tr>
<tr>
<td>James, Alison, 270</td>
<td>Leydon, G.M., 47</td>
</tr>
<tr>
<td>Japan, 182.1, 378</td>
<td>Lobban, F., 41</td>
</tr>
<tr>
<td>Johnson, Virginia, 332, 335</td>
<td>long-term physical conditions (LTCs) and mental health. See physical conditions (long-term) (LTCs)</td>
</tr>
<tr>
<td>Kabatt-Zinn, Jon, 432–433</td>
<td>Lorig, Kate, 48</td>
</tr>
<tr>
<td>Katon, Wayne, 404</td>
<td>Lovell, Karina, viii–ix, 420–434</td>
</tr>
<tr>
<td>Kegel exercises, 335</td>
<td>low and middle-income (LAMI) countries overview, 54–64</td>
</tr>
<tr>
<td>Kessler, D., 462–463</td>
<td>mental health teaching in, 454, 455</td>
</tr>
<tr>
<td>mental disorder neglect in, 54</td>
<td>methodology unexplained symptoms (MUS). See also physical conditions (long-term) (LTCs); somatic issues</td>
</tr>
<tr>
<td>population by diagnosis, 54</td>
<td>overview, 138–148</td>
</tr>
<tr>
<td>mortality in, 56, 57, 58, 59</td>
<td>aetiology of, 142–143</td>
</tr>
<tr>
<td>Movement for Global Mental Health and, 62</td>
<td>anxiety and, 19–20</td>
</tr>
<tr>
<td>PCMH in, 54, 55, 61–64</td>
<td>in case studies, 139–140, 142, 144–145</td>
</tr>
<tr>
<td>populations per doctor in, 60</td>
<td>in children and adolescents, 202</td>
</tr>
<tr>
<td>SDGs for, 58box5.2, 59</td>
<td>service and training packages for, 54–55</td>
</tr>
<tr>
<td>secondary care in, 55, 64</td>
<td>specialist services in, 60, 64</td>
</tr>
<tr>
<td>sustainable development goals for, 59</td>
<td>World Bank classification of, 563.1</td>
</tr>
<tr>
<td>universal health coverage and, 58box5.2, 59</td>
<td>Luxembourg, 375</td>
</tr>
<tr>
<td>World Bank classification of, 565.1</td>
<td>major depression. See depression (major)</td>
</tr>
<tr>
<td>malaria, 57</td>
<td>Malta, 375</td>
</tr>
<tr>
<td>Manchester (UK), 182.1, 304</td>
<td>Masters, William, 332, 335</td>
</tr>
<tr>
<td>Masters, William, 332, 335</td>
<td>maternal health issues. See perinatal mental health problems</td>
</tr>
<tr>
<td>medical care in, 38–39, 59</td>
<td>Mauss, M., 24–25</td>
</tr>
<tr>
<td>mental health burdens in, 59</td>
<td>MDD (major depressive disorder subscale), 70–72, 79, 80</td>
</tr>
<tr>
<td>mental health teaching in, 454, 455</td>
<td>MDMA (ecstasy). See drug use disorders; psychotic disorders</td>
</tr>
<tr>
<td>see also drug use disorders; psychotic disorders</td>
<td>Meadows, G.N., 406</td>
</tr>
<tr>
<td>medicalization, 20, 32, 42, 62</td>
<td>medicalization, 20–21</td>
</tr>
<tr>
<td>medically unexplained symptoms (MUS). See also physical conditions (long-term) (LTCs); somatic issues overview, 138–148</td>
<td>anxiety and, 19–20</td>
</tr>
<tr>
<td>in case studies, 139–140, 142, 144–145</td>
<td>in children and adolescents, 202</td>
</tr>
</tbody>
</table>
chronic fatigue syndrome, 19, 138
classification of, 138–140
clinicians’ management of, 147box10.1
collaborative care for, 146
consultation with patients and, 144–145
definitions and characteristics, 138, 202
empathy and, 26
Extended Reattribution and Management model for, 146
healthcare providers impact on, 142
iatrogenesis in, 143, 144–145, 146, 147box10.1
identification of risk factors for, 143
irritable bowel syndrome, 138
key points of, 148box
maintaining factors in, 142
management of patients with, 147box10.1
mild, 144
moderate, 145–146
neurophysiological changes and, 142–143
patient management, 144fg10.4, 144–146
persistent, 144–145
pharmacological treatments for, 146
physical conditions and, 144–145
physical management of, 147box10.1
presdisposing factors in, 142
prevalence of, 141fg10.2
psychiatric disorders associated with, 19
psychological management of, 147box10.1
psychopharmacological management of, 147box10.1
self-help for, 145
severe/chronic, 146–148, 147box10.1
terminologies describing, 138
triggers of, 142
uncertainty levels in treatment of, 148
medication. See antidepressant medications;
benzodiazepines; child and adolescent mental health problems;
depression; drug dependence; education and training model;
general practitioners;
patients/service users;
SSRIs
mental health. See general practitioners and mental health;
mental health research in primary care;
perinatal mental health problems; physical conditions (long-term)
(LTCs); primary care mental health (PCMH);
prison populations and offenders; public mental health;
sociological views of mental health and illness; teaching and learning about mental health
mental health defined, 3, 28, 356–357
Mental Health Expert Committee of the World Health Organization, 54
Mental Health First Aid Lite training sessions, 45
mental health Gap Action Programme. See mhGAP mental health policy, 6–7
mental health research in primary care overview, 459–469
case-control studies in, 462
clinical practice observations in, 463
cohort studies in, 462
constant comparison studies in, 465
controlled trials in, 463–464
cross-sectional studies in, 462
disorder study descriptions in, 461–463
ethnographic studies in, 466
evaluation of offers to participate in, 460, 461box31.2
factors affecting practitioner involvement in, 459–460
grounded theory studies in, 465
key points of, 470box
longitudinal studies of, 462–463
Michael Moore’s career trajectory in, 468–469
mixed method research in, 466–467
vs. mortality, 356–357
the need for, 459, 470box
PCMH clinicians, 478
PCMH practitioners’ development and delivering, 467–468, 470box
poverty and, 462
qualitative studies in, 461–465, 470box
quantitative designs in, 461–465, 470box
questions to consider for participation in, 460–461box31.2
randomised controlled trials in, 459box31.1
recall bias in, 462
research networks’ roles in, 467, 470box
respondent validation in, 465
services provision determined by, 459
sociological factors in, 462
surveys in, 461
systematic reviews in, 464–465
triangulation of data in, 465
mental illness. See specific mental health problems
mental illness defined, 70
Mercer, Stewart W., ix, 175–181box12.3
mhGAP (mental health Gap Action Programme), 54, 62, 64, 79, 81
Millennium Development Goals (MDG), 57–59, 58box5.2
mindfulness-based therapy aims of, 432–433
in case study, 134
as CBT, 132–133, 424
core practice of, 433
effectiveness of, 96–97, 433
as first line of treatment, 135
Mindfulness-Based Stress Reduction, 180
in wellbeing, 361, 483
as whole system intervention, 180
models of service. See collaborative care; consultation-liaison model; education and training model; pathways to care model; psychological therapy referral model; stepped care
Moore, Michael, ix, 459–469
morbidity. See also comorbidity; multimorbidity
alcohol use problems and, 253
depression and, 74
drug use disorders and, 245
extent of, in mental illness, 6, 12
LTCs and, 16–17, 175
patients’ needs and system responses to, 43
Psychiatric Morbidity Surveys, 14
psychotic disorders and, 218, 221
self-harm and, 103, 118, 201
suicide and, 103, 118, 201
surveys on, 12, 14, 16
motivational interviewing, 422–291, 434
Multidimensional Poverty Index, 56box.5.1
multimorbidity. See also comorbidity; morbidity
autism spectrum and, 203
collaborative care and, 178
depression and, 175–176
inverse care law and, 181
LTCs and, 175–176, 177–178, 179, 181
in older people, 175–176
pathology overlaps and, 74–76
single disease focus vs., 2
socioeconomic status and, 175, 176–177
whole systems interventions for, 180
National Comorbidity Survey, 14
National Confidential Inquiry, 108, 114
National Institute for Health and Clinical Excellence. See NICE
Netherlands anxiety disorders in, 125
ICD-10 used in, 70–72
nurse-led clinics in, 375
nurses trained for specialist roles in, 375
psychiatric disorder prevalence in, 181.2
refugees in, 311
schizophrenia rates in, 300–301
stepped RTCs in, 408, 411
New South Wales, 289–290
New Zealand, 75–76, 98, 126, 127, 216–217
Nicaragua, 61
NICE (National Institute for Health and Clinical Excellence) guidelines for access to mental health care, 387–388
on alcohol dependence, 261
for antidepressants, 94–95
for anxiety disorders, 134
for assessment following self-harm, 107, 108
for childhood depression and anxiety, 203–204, 205–207
for depression management, 80, 92, 463, 473–474
development of, 40, 134
for eating disorder screening, 270
for exercise as therapy, 424–425
for GAD, 131–134
for holistic care, 134
Lester Positive Cardiometabolic Health tool endorsed by, 294–295
for LTC comorbidity, 177
Moore as contributor to, 469
for patients/service users, 40
for PCMH services for mental illness, 293, 294–295
for postnatal depression medication, 193
for public mental health, 360
specialist mental services, 278–279
on SSRIs, 94–95
for stepped care, 91, 409, 420
Nigeria, 182.1
Norway, 218, 300–301
nurses brief intervention training of, 258–259
in case studies, 154, 170, 171, 176–177
179
179box12.2, 226, 258, 349
clinics led by, 375
in collaborative care, 30, 179box12.2, 379
as communicators, 41–42
confidence issues of, 379, 380
depressed patients supported by, 378
health centres run by, 60
Lester’s proposals for, 294–295
mental health training of, 376, 377–378
older people treated by, 160
patients’ preferences for, 41–42
in patients’ questionnaire evaluating, 44box4.2
PCMH obstacles to, 379
in PCMH teams, 2, 5, 46, 375, 381
PCMH training requirements of, 376
physical illness monitoring by, 380
in prison PCMH teams, 348, 349

© in this web service Cambridge University Press
www.cambridge.org
access to mental health care for, 390
as asylum seekers/ refugees, 318
collaborative care for, 172box
distress among, 318
GPs’ roles in mental health of, 171
health services undereused by, 386
holistic treatments for, 172box
multimorbidity in, 175–176
PCMH for, 106, 171, 172box
recognition of symptoms in, 172box
older people (delirium in) overview, 153–158
antidepressants for, 156box11.2
in case studies, 154, 158
definitions and characteristics, 153
delusions and, 153
dementia and, 227
vs. depression or dementia, 153/11.1
diagnosis of, 154–155
hyperactive, 154
hypocotonic, 154
management principles for, 155–157, 158
mental capacities and, 157–158
mixed, 154
Parkinson’s disease and, 155–157
physical health problems and, 154, 155box
precipitants of, 156box11.2
presentation of, 153–154
referred to mental health services, 158
risk factors for, 155box11.1
triggers of, 154
older people (delusions in), 153, 154, 160, 170–171
older people (dementia in) overview, 163–170
Alzheimer’s disease and, 163box11.6, 163–164, 165, 166, 168, 169
cardiovascular disease and, 163–164
in case studies, 163, 169
causes of, 163box11.6
cognitive testing and screening for, 166, 167/11.3, 169
definitions and characteristics, 163, 165–166
delirium and, 227
vs. delirium or depression, 153/11.1
delusions and, 153, 154, 170–171
depression and, 159, 168
diagnosis of, 164, 166
driving and, 167
drug treatments for, 165–166, 168–169
epidemiology of, 163–164, 164/11.2
frontotemporal dementia and, 166
GPs’ roles in managing, 169
imaging of, 170
investigations of, 167
Korsakoff’s psychosis and, 166
Lewy-body disease and, 155–157, 163box11.6, 165–166, 169
management of, 168
mild cognitive impairment in, 170
mixed dementia and, 165
Parkinson’s disease and, 155box11.1, 163, 165–166, 169
physical health problems and, 169
prevalence of, 154/25.1
prevalence of, in the future, 16
psychological therapies for, 168
risk assessment for, 164–165, 165box11.7, 169
testing and screening for, 166, 167/11.3, 169
vascular dementia and, 163box11.6, 164, 165, 169, 170, 171
older people (depression in) overview, 158–162
antidepressants for, 28, 159, 160–161, 162
anxiety combined with, 159, 161

nurses (cont.)
SMI patients and, 391–392, 406, 455
SMI patients’ referrals too, 454–455
specialist development encouraged for, 5
therapies administered by, 93–94, 132–133, 376
training in specialist care, 375, 377–378
training requirements for, 376
working in prisons, 347
working with SMI patients, 391–392

Nutt, David, 238

obesity. See also eating disorders
cardiovascular disease and, 281/20.3, 289
medications prescribed for, 287
mental illness and, 279–280, 285/20.2, 288–290, 295box
prevalence of, 289
psychotic disorders and, 218
pulmonary disorders and, 292
schizophrenia and, 278/20.1, 289
obsessive-compulsive disorder (OCD)
characteristics of, 128–129/9.2
diagnosis of, 130
as disabling, 125
first, second and third line medication for, 133/9.3
perinatal, 187
prevalence of, 126/9.1, 354/25.1
in prisoners/offenders, 343, 345
triggers of, 128–129/9.2
Ödegaard, O., 301
OECD nations, 373–374, 375, 377, 379, 380
older people (general)
overview of medical problems in, 153, 172box11.8
abbreviated mental test score for, 157box11.3

© in this web service Cambridge University Press
www.cambridge.org
bereavement and, 159
in case studies, 159, 161–162
clinical evaluation of, 160
collaborative care for, 160
comorbidity and, 159
vs. delirium or dementia, 153r.11
dementia and, 159, 168
diagnosis of, 159
epidemiology of, 158–159
family relations and, 161
Geriatric Depression Scale for, 177
intervention economics of, 362r.25.6
management principles for, 160
PCMH screening for, 160box11.4
physical activity and, 161
physical health problems and, 159, 160box11.4, 162, 171, 172box11.8
prevention of, 359
psychological interventions for, 161
referrals to health services for, 162box11.5, 162
risk factors for, 160box11.4
specialist care for, 162box11.5, 162
sub-syndromal symptoms, 158–159
O’Neill, Siobhan, ix, 103–119
on-line therapy, 46
oppositional defiant disorder, 201–202, 203, 206r.14.2
Osborn, D.J.P., 462
Pakistani ethnic minorities, 40, 301, 304, 306, 466
Panagioti, M., 485
panic attacks, 125, 129–130, 216, 244, 312
panic disorder
in acute mental health emergencies, 228
agoraphobia and, 129–130
benzodiazepines for, 133–134
CBT for, 132–133
diagnosis of, 129–130
first, second and third line medication for, 133r.9.3
management of, 131
panic attacks vs., 129–130
perinatal, 187
prevalence of, 125, 126r.9.1
prognosis for, 126
triggers of, 128r.9.2–129r.9.2
Parkinson’s disease
in case study, 423
delirium and, 155box11.1
dementia and, 155–157, 163, 165–166, 169
pathways to care model, 7, 13–14, 402
Patient Health Questionnaires. See PHQs
Patient Participation Groups (PPGs), 49
patient reported outcome measures (PROMs), 92, 129
patient-centred therapies and services
access to mental health care and, 434
authors’ preferences for, 3
in case study, 424–425
collaborative care and, 404, 405, 406
costs of, 403
in financially deprived areas, 176
future developments for, 413
mental health applications of, 440–445r.30.1
other therapies and, 403
patients’ preferences for, 402
patients/service users. See also stigmatization overview, 39–49
choice as component in involvement of, 48–49
collaborating in recovery, 46, 48–49
community-based services preferred by, 47–48
confidentiality as priority of, 46
continuity of care as priority of, 41–42, 45, 49–50box, 218–219
defined, 8–9, 39
demographics of higher health-care involvement, 49–50box
depression experiences described by, 40–41, 42–43
exposure of, 40, 48
GP’s rated by, 43
initiating PCMH, 18–19
involved in mental health care, 39–40
key points of, 49–50box
lack of control sensed by, 42
medication concerns of, 47
mental health care perspectives of, 40
needs and expectations of, 45–46
optimism as a priority among, 219–220, 221–222
patients’ comfort levels with, vs. doctors, 41–42
PCMH as viewed by, 42–44
primary care environment for, 45
priorities as reported by, 43box4.1
psychological therapies for, 46–47
psychologically informed environment for, 45
with psychotic disorders, 41, 49–50box
stigmatization of, 19–20, 25, 27, 42
stress-related needs of, 4, 43, 49–50box
trust as priority of, 34box3.1, 40, 46
PCMH. See primary care mental health
Pendleton, D., 451
performance anxiety, 133–134
perinatal mental health problems (general) overview, 185–196
alcohol use problems and, 187
antenatal depression, 186–187
baby blues, 187, 196box
bipolar disorder and, 185, 189, 194
burdens of, 195
in case study, 190
children affected by, 185, 192box13.2
classification of, 186
perinatal mental (cont.)
depression history as risk
factor for, 190, 194
detection and diagnosis
of, 190
domestic violence and, 185
drug misuse and, 187
eating disorders and, 185
epidemiology of, 186–187
identification of, 185,
196box
key points of, 196box
management of, 191
maternal mortality rates
and, 185
medication for, 185, 193,
196box
midwife training in, 195
organization of care for,
195–196
in parents, 185, 358–359
PCMH teams roles in
training, 196box
prediction of, 188–190
during pregnancy, 358
psychological approaches to,
196box
psychosis and, 185, 187, 188,
189, 194, 196box
PTSD and, 185, 193
risk factors for, 189box13.1
RTGs for, 191
schizophrenia and, 189, 194
screening for, 188–189,
196box
social support vs., 185
perinatal mental health
problems (postnatal depression)
antidepressant medication
for, 186, 194box13.3
in Black Caribbean
immigrants, 301
burdens of, 195
in case studies, 190
children affected by, 185,
192box13.2
cultural expressions of, 188
in ethnic minorities, 301
medication for, 193–194,
194box13.3
medication risks in, 193
onset of, 188
prevalence of, 185, 187, 188,
196box
prevention of, 185
psychological approaches
to, 191
PTSD and, 186–187, 193
risk factors for, 189box13.1
in South Asian women, 29–30
symptoms of, 190
treatments of, 192box13.2
personality disorders
access to mental health care
lacking for, 393–394
borderline personality
disorder, 72, 343
definitions and
characteristics of, 72, 228
life expectancy reduced by,
355f25.4
mortality and, 27920.1
in prisoners/offenders,
343
person-centred therapy model,
421–424, 423ff29.2,
426–427, 434box
Pescosolido, B.A., 30–31
Peveler, Robert, ix, 1–9, 19,
277–295, 459–469
Philippines, 61
phobias, 128–129
196, 130, 133–134, 354f25.1
PHQs (Patient Health
Questionnaires)
in the Doncaster/Newham
studies, 408
on depression (general), 80,
87, 92, 134, 159, 177
on depression (major), 87,
88box7.1, 473–474,
475, 477
for risk factor predictors and
identification, 143ff10.3
on somatic symptoms,
80, 143
in stepped care, 408, 410
physical problems (long-
term) (LTGs)
overview, 175, 181box12.3
bi-directionality of, 175
burdens of, 355–356
CARE Plus intervention
for, 180
in case studies,
176–177box12.1,
179box12.2
Chronic Care Model for, 178
collaborative care for,
178–179, 179box12.2
comorbidity and, 175
delirium in older people and,
154–155
depression and, 90box7.2, 91,
92, 177–179, 180,
181box, 379
depression in older people
and, 159, 160box11.4, 162,
171, 172box
GP s roles in management of,
179box12.2
inverse care law and,
176–177box12.1, 176
key points of, 181box
management of, 177–180,
181box
mental illness and, 73–74,
82box, 355–356
mindfulness-based
interventions for, 180
morbidty and, 175
mortality and, 16–17, 175
multimorbidity and,
175–178, 176–177box12.1,
179, 181box
MUS and, 138, 143, 144–145
numbers of, vs. types of, 175
organizational interventions
for, 178–180
psychological therapies for,
178, 422box29.1
psychotic disorders and,
218, 221
recognition and assessment
of, 177
SMI combined with, 380
socioeconomic status and,
175, 176–177box12.1, 357
somatoform disorders
and, 141
suicide and, 104, 105,
119–120box, 232
whole systems interventions
for, 180, 181box
physical health of people with
mental illness
overview, 277–295
cardiovascular disease
affecting, 17, 280,
281box20.3, 285
in case study, 277
community-based care
for, 293
comorbidity and, 277–278
diabetes affecting, 28120.3,
283ff20.2,
286box20.2, 289
dyslipidaemia affecting, 280, 281f, 290.3
HIV affecting, 292
holistic care for, 277–279
hyperprolactinaemia affecting, 290b, 290.3
hypertension affecting, 281, 285
life expectancy and, 279f, 292
lithium treatments for, 293
mortality and, 279f, 280f, 290.3
obesity affecting, 281f, 290.3
osteoporosis affecting, 290b, 291f, 291
PCMH reviews for, 293–295, 295b
programme accessibility for, 288
pulmonary disorders and, 292
risk assessment models for, 282
screening, 283–284f, 290.4
smoking affecting, 281f, 282
specialist services for, 293
statin treatments and, 282
weight changes and, 287, 288, 289–290
weight changes in, 287f, 290.3
PICO treatment approach, 476b, 476–478, 479b
Pilgrim, David, ix, 24–36
Pincus, H.A., 76
Poland, 374, 375
Portugal, 375
postnatal/postpartum depression. See perinatal mental health problems (postnatal depression)
post-traumatic stress disorder (PTSD)
antidepressant medication for, 193
in asylum seekers/refugees, 311, 313
characteristics of, 128–129f, 292
diagnosis of, 131
as disabling, 125
eye-movement desensitization for, 133–134
first, second and third line medication for, 133f, 3.3
GPs with symptoms of, 484
perinatal, 186–187
premenstrual, 186–187, 193
prevalence of, 16, 126f, 1.1, 354f, 25.1
in prisoners/offenders, 343, 345
triggers of, 128–129f, 9.2
poverty
asylums seekers and refugees, 311, 313, 322b
common mental health problems and, 63–64
depression (general) and, 286
drug use disorders and, 240
mental health research in primary care and, 462
PCMH and, 57, 59, 63–64, 98
SDGs addressing, 58b, 5.2
PPGs (Patent Participation Groups), 49
primary care mental health (PCMH). See also anxiety; cognitive behaviour therapy; depression; emergencies in primary care; low and middle-income (LAMI) countries; mental health research in primary care; nurses; patients/service users; psychotic disorders; public mental health; sociological views of mental health and illness
overview, 1–9
advantages of, 4–5
aims/definitions/features of, 1–2, 381, 401–402
disadvantages of, 4–5
integrated into health care systems, 7, 8b, 1.1, 9, 54, 61f, 62, 374, 381
key points of, 9b
as primary provider of mental healthcare, 36b, 42, 402, 466
primary care mental health teams. See also nurses
overview, 373–381
anxiety disorder management by, 376–377
anxiety management by, 376–377
attitudes in, toward mental health problems, 377–378
basic functions of, 373
care enhancement by, 377–379
CBT offered by, 376
clinicians’ attitudes toward mental health issues and, 378, 381b
collaborative care and, 376
common mental problems addressed by, 376–377
comprehensive services provided by, 375
depression management by, 376–377
enhanced roles of, 381b
focus on, 9
GP integration into, 375
GP practice as separate from, 375
GP training in, 375
GPs in, 5, 9
holistic care provided by, 172b, 222b
IAPT programme and, 376
integrated care coordination by, 381
IT resources available to, 380–381
key points of, 381b
knowledge and attitudes of, 377–378
mental health skills required in, 381b
mental illness outcome disparities and, 373–374
new roles for, 376
older peoples’ care provided by, 171
patients/service users of, 8–9
practitioners in, 375
in perinatal mental health, 196b
questionnaires submitted to, 375, 378
SMI care provided by, 379–381, 381b
as stepped care providers, 8
stigmatization addressed by, 4, 374, 381b, 381
structure of, 5f, 1.1
suicide prevention by, 118
Aetiology and Ethnicity in Schizophrenia and Other Psychoses (AESOP) study, 215
randomised controlled trials. See RTCs
RCGP. See Royal College of General Practitioners
refugees. See asylum seekers and refugees
Reilly, S., 391
research in PCMH. See mental health research in primary care
Richards, David A., ix, 388, 401–413
Robinson, Louise, ix, 153–172box11.8
Rogers, Anne, ix, 24–36
Rosendal, Marianne, ix, 138–148
Royal College of General Practitioners (RCGP), 195, 376, 439, 440–445/30.1, 485
RTCs (randomised controlled trials)
alalysis revealing flaws in, 466
barriers to clinician participation in, 459box31.1
for major depression, 473–474
research in primary care and, 459–460
in stepped care, 408–409
in treatment decisions, 473–474, 475
treatment effectiveness determined by, 464
treatment efficacy determined by, 463–464
Russia, 97
Salmon, P., 465–466
Scandinavia, 216–217
schizophrenia. See also psychotic disorders
access to mental health care for patients with, 391
burdens of, 17
cardiovascular disease and, 281/20.3
in case studies, 226, 277
collaborative care for
patients with, 405–406
comorbidity and, 277–278, 278box20.1
cost savings for, 364
delusions and, 170
as dementia praecox, 219
disabling nature of, 17
dyslipidaemia and, 280–281
in ethnic minorities, 300–301
Initiative to Reduce the Impact of Schizophrenia, 217
life expectancy and, 279/20.2, 355f/25.4
medication for, 193, 194
mortality and, 277, 279/20.1, 280fg/20.1
National Audit of Schizophrenia, 294
obesity and, 278box20.1, 289
patients’ descriptions of, 41
PC vs. specialist interests in, 447
PCMH and, 3–4, 14
perinatal mental health problems and, 194
prevalence of, 15–16
as purerpal risk factor, 189
QOF and, 294, 393
secondary care for, 12
smoking and, 218, 281/20.3
specialist care and, 3–4
as suicide risk factor, 231–232box16.2
weight changes and, 287, 288
Schmidt, Ulrike, ix–x, 267–273
SCOFF questionnaire, 270–271
Scotland, 175, 236, 277, 294n1, 377–378, 395
Scott, S., 203–204
SDGs (Sustainable Development Goals), 58box5.2, 59, 64
self-harm
as addictive, 105–106
anxiety disorders and, 134
assessment of, 105–106
causes of, 104, 105–106
in children and adolescents, 201
in depression assessment and management, 449–450box30.2
disease burden of, 353
cost savings for, 364
delusions and, 170
as dementia praecox, 219
disabling nature of, 17
dyslipidaemia and, 280–281
in ethnic minorities, 300–301
in female prisoners, 343
interventions for, 106, 117–118, 360
morbidity and, 103, 201
mortality from, 103, 107box8.1
non-suicidal, 106fg/8.2, 106
in older people, 160, 161–162
prevalence of, 16
in prisoners/offenders, 345
rates of, increasing, 16
repeated, 105–106, 107box8.1
safety plans for, 117
stress and, 103, 105–106
in young people, 114, 355f/25.3
self-help therapies
advocated, 48–49
for asylum seekers/refugees, 333–334
behavioural activation and, 424–425
bibliotherapy and, 425
bibliotherapy for, 433
brief intervention in, 425–426, 427–428, 434box
in case study, 424–425
CBT and, 424
counselling in, 426–427, 434box
effectiveness of, 425
for ethnic minorities, 306
exercise and, 425, 433
exposure therapy, 428
five-stage approach in, 428box29.4
for GAD, 132
health technologies for, 425
for LTGs, 178, 181box
motivational interviewing and, 425–426
for MUS, 145
as new field in PCMH, 32, 36box
patients’ preference for, 46
prevalence of, 35
principles of, 424

© in this web service Cambridge University Press
www.cambridge.org
problem-solving therapy in, 427–428, 428
in psychological therapies, 420
for sexual problems, 333–334
solution-focus therapy in, 427
for somatic symptoms, 34
stages of change in, 425, 426
in stepped care, 406–407
for technology-mediated self-help therapies, 34
Senegal, 61
service users. See patients/service users.
severe mental illness. See also bipolar disorder; psychotic disorders; schizophrenia
access to mental health care for patients with, 391–392
for collaborative care for, 397, 405–406
comorbidity monitoring and research in, 380–381, 462
financial incentives for treatment of, 397
health systems lack of coordination regarding, 380
medication prescribed for, 391–392
nurses working with patients with, 391–392
OCED expenditures on, 379
optimism as a priority in patients with, 466
PCMH as central to patients with, 379, 466
PCMH teams’ roles in treating, 379–381, 381
physical illness combined with, 380
randomised controlled trials for, 454–455
registers of patients with, 3, 293, 380, 391–392, 454–455
secondary care for, 12
as specialist health services focus, 379
stigmatisation of, 380
sexual problems overview, 327–338
anxiety about, 328, 331, 332–333, 334, 335, 336, 337, 338, 339
arousal problems, 328
in case study, 338
CBT for, 335–336
comorbidity in, 331, 336 definitions and classifications of, 327–328
delayed ejaculation, 335–336
depression and, 331, 334, 336
desire problems, 328, 329/23.1
detection of, 330
as DSM-5 disorders, 336
dyspareunia, 329/23.1, 337
ejaculatory disorders, 329/23.1, 334–337
epidemiology of, 329–330
erectile disorders, 328, 329/23.1, 330, 331, 332–334, 338, 339/box
female genito-pelvic pain/penetration disorder, 328
female orgasmic disorder, 328
female sexual interest/arousal disorder, 328, 329/23.1, 336–337
Framework for Sexual Health Improvement, 327
help-seeking and, 327
hyperprolactinaemia and, 290/box
investigations of, 331
life expectancy reduced by, 360
Male Hypoactive Sexual Desire Disorder, 328
management of, 332–338
medications prescribed for, 331–332, 333, 334–335, 336, 339/box
orgasmic disorders, 328, 329/23.1, 334–337
pain issues as, 328
PC vs. specialist interests in, 447
performance anxiety, 332, 334
pornography and, 331, 333–334
premature (early) ejaculation, 327, 328, 329/23.1, 334–335
prevalence of, 329/23.1
questionnaires regarding, 330
research in, 332
screening of, 331
sexual histories of, 330
stress/distress caused by,
testosterone screening in,
sexual histories of, 330
screening of, 331
research in, 332
bipolar disorder and, 218,
schizophrenia and, 218,
levels and, 355
health risk and exclusion
life expectancy reduced by,
during pregnancy, 358
prevalence of, 354/25.1, 355
as preventable cause of death, 355
psychotic disorders and, 218,
schizophrenia and, 218,
Pulmonary Embolism
Life Expectancy and, 253
prevalence of, 354/25.1, 355
as preventable cause of death, 355
psychotic disorders and, 218,
schizophrenia and, 218,
social anxiety disorder (social phobia), 127, 128–129t9.2, 130, 133t9.3, 133–134
Social Functioning Questionnaire (SFQ), 81
sociological views of mental health and illness overview, 24–36
access to health care in, 30–31, 36box
age-related issues in, 28
conclusions regarding, 35–36
fiscal burden issues in, 25–26
gender issues in, 27–28
GP’s roles re-orientated in, 25
habitus in, 24–25, 31
help-seeking and, 27, 28–29, 29–31
integration of patients into general population, 39
key points of, 36box
new developments in, 25–27
PCMH’s role in, 24–25
race-related issues in, 28–30
social inequalities and, 27, 34box3.1
social networks and, 30–31, 31n2, 34–35
study sources in, 24n1
therapeutic alliances and, 34box3.1
treatment issues in, 31–33
solution-focused therapy, 116, 119, 422n29.1, 424n29.2, 434
somatic issues. See also medically unexplained symptoms; psychological therapies in asylum seekers/refugees, 312, 317
biological mechanisms in, 142
in case study, 140–141
vs. depression, 90
as DSM-5 disorder, 75
in ethnic minorities, 304
GPS’ vs. specialists’ interests in, 447
healthcare providers and, 142
in LAMI countries, 62
mortality and, 279n20.1
multimorbidity in, 74–75
PHQs for, 80, 143
physical conditions combined with, 141, 447
as physical expressions of distress, 317
psychological therapies for, 422box29.1
questionnaire measurement of, 143
self-help therapies for, 34box3.1
symptom requirements of, 138
South Asian minorities. See also ethnic minorities
AMP psychosocial intervention for, 390
in case study, 302
collaborative care among women among, 301
comorbidity in, 301
depression in women among, 29, 301
depression undiagnosed by PCMH for, 303–304
maternal mortality rates in, 56
postnatal depression in, 29–30, 301
somatic issues in women among, 29, 41
support groups for, 302
treatment-seeking lacking in, 301
South East Asia, 54
Spain, 125, 374, 375
Spiers, J., 485
SSRIs (selective serotonin reuptake inhibitors). See also antidepressant medications for anxiety disorders, 133
in case study, 176–177box12.1
controversies about, 47
for depression in older people, 160–161
effectiveness of, 194
as first-line anxiety medication, 133n9.3
long-term use of, 95–96
NICE guidelines for, 94–95
for postnatal depression, 193
risks of, 33, 94–95, 128
for sexual problems, 334
sexual problems and, 332
suicide and, 233
in treatment decisions, 475
stepped care overview, 401–413
acceptability and attendance, 410–411
aims and principles of, 8, 406, 413box, 420
for anxiety, 406, 407, 412
in care pathway restructuring, 394
in case study, 411–413
CBT in, 406–407
for children and adolescents, 209–210box
critiques of, 409–410, 411
for depression, 91–97, 177, 406, 407, 408
for MUS, 144
future developments for, 413
GAD-7 scores in trials of, 408
IAPT guidelines for, 407–409, 410
key points of, 413box
least burden principle in, 406, 409
LTCs and, 177, 181box
monitoring of, 410
for MUS, 144n10.4
NICE guidelines for, 409, 420
by PCMH teams, 8
Personalised Advantage Index, 409
PHQ-9 scores in trials of, 408–409
progressive vs. stratified, 409–410
psychological therapies in, 406–408, 409, 410–413
psychological therapy referral model and, 406
RCTs for, 408–409
self-correction in, 406
self-help therapies in, 406–407
service delivery issues in, 409–410, 413box
stratified vs. progressive, 409–410
stigmatization of alcohol use problems, 253 in asylum seekers/refugees, 314
of substance misuse/abuse
of borderline personality disorder, 72
in Central/Eastern vs. Western Europe, 374–375
the CMHT model and, 393–394
of depression, 26, 474
of eating disorders, 269 of GPs experiencing mental health problems, 482 interventions for, 359, 360, 362–364 in LAMI countries, 54 of patients, 19–20, 25, 27, 42
PCMH teams addressing, 4, 374, 381 box, 381 of prisoners/offenders, 344–345
psychotic disorders and, 31, 220
of self-harm, 118 of SMI, 380 suicide-related, 103–104, 110, 114
stress and distress. See also post-traumatic stress disorder; psychological therapies; self-harm; sexual problems; suicidal behaviour/attempts; suicidal thoughts/ideation; suicide #DearDistressed Project, 121 adjustment disorder and, 88–89 among asylum seekers, 311, 322 box
Bank of Hope strategies for minimizing, 115–116
behavioural activation addressing, 430 bereavement as, 87
bodily stress disorder, 75 burn-out and, 481 burn-out as cause of, 481 CBT and, 26–27 communication of, in suicide risk assessment, 109–110
counselling and, 427 dementia and, 168 depression caused by, 40 detection of, by GPs, 447–449 vs. disorder, 73 eating disorders causing, 267–268 vs 19.1 employment-related, 359 in ethnic minorities, 307 among GPs, 480–481, 483
GPs’ evaluation of physical problems and, 44 box 4.2 help-seeking and, 30, 31 major depression and, 87 management of, 447 medication for, 32, 33 mindfulness-based reduction of, 132–133, 180 mindfulness-based therapy addressing, 432–433 over sexual problems, 327 in patients, 43, 49–50 box PC vs. specialist interests in, 447
PCMH consultations prompted by, 3 PHQ-9 scores for, 88 box 7.1 during pregnancy, 358 psychological therapies for, 420, 422 box 29.1 as psychosis precursor, 214 box 15.1 racial minorities’ experiences of, 30–39 safety plans addressing, 113 box, 117 social stress, 716.1 solution-focus therapy addressing, 117 suicide and, 108, 112 box 8.3, 114, 116 box 8.4 timing of depression treatment and, 89 trigger identification, 116 box 8.4 Sub-Saharan Africa, 54 substance misuse/abuse anxiety disorders and, 75–76 burdens of, 373 coexisting with other disorders, 75–76 depression and, 90 box 7.2 eating disorders and, 268 among GPs, 484 mental illness caused by, 253 mortality and, 279/280.1 in prisoners/offenders, 343, 344 in psychosis, 216 SDGs for, 59 starting ages of, 354/25.2 suicide and, 108, 231–232 box 16.2 sub-threshold disorders in bulimia nervosa, 268 characteristics of, 76 depression-related, 76, 88, 89, 91 is eating disorders, 273 in prisoners/offenders, 343 seriousness of, 76 transitioning to threshold disorder, 353
suicide (general) (cont.)
rates of, 231
same-sex orientation and, 231–232 box 16.2
socioeconomic status and, 231–232 box 16.2
stress caused by, 103
the wish to feel better vs., 116 box 8.4, 119–120 box young people and, 114
suicidal behaviour/attempts
assessment of, 107–111, 112 box 8.3
causes of, 104
as a continuum, 103–104, 107, 109 box 8.2
diagnostic criteria for, 72 box 6.2
masculine sociological standards and, 28
prevalence of, 356 box 25.5
stress accompanying, 107–108
vs. suicidal thoughts, 103–104
by women, 231–232 box 16.2
by young people, 114
suicidal thoughts/ideation. See also self-harm
Bank of Hope strategies for minimizing, 116 box 8.4
benzodiazepine use and, 244
in case studies, 113
in case study, 113
causes of, 103–104, 105
in children and adolescents, 205 t 14.1
deaths by, in the UK, 103
depression and, 127
development of, 104, 105 box 8.1
distress and, 103–104
leading to attempts, 110–111
mental disorders/illness and, 104
mental state examination and, 112 box 8.3
patient confidentiality and, 111
patients’ disclosure of, 108–110, 111, 119–120 box
physical health problems and, 105
prevalence of, 356 box 25.5
in psychosis, 216
rates among women, 103
referrals to health services for, 233–234
vs. suicidal behaviour/ attempts, 103–104
trigger events of, 112
in young people, 114
suicide prevention
overview, 103–119
Bank of Hope strategies for, 115, 116 box 8.4
barriers to, 103
collaborative care in, 115, 119–120 box
compassion in, 103, 106, 119
cost savings for, 364
GPs’ roles in, 103, 104, 106, 115, 117–118, 119–120 box
high risk groups as priorities for, 232
intervention economics of, 362 box 25.6
interventions for, 359, 360
key points of, 119–120 box
medication in, 118, 193
patient-monitoring after hospitalization and, 233
PCMH’s roles in, 104
physical health problems and, 119–120 box
QOF and, 104
referrals to mental health services, 115
resources for, 121
risk assessment and mitigation in, 103, 232
safety plans for, 103, 112, 113 t, 115–116, 117
solution-focused therapy for, 119
strategies for, 103, 112, 113 t, 115, 116 box 8.4
suicide-means access limitations in, 233
Triangle of Care in, 111
Sumathipala, Athula, ix–x
Survivors Speak Out campaign, 39–40
Sustainable Development Goals (SDGs), 58 box 5.2, 59, 64
Sweden, 374, 453
Switzerland, 60 box 5.2, 375
talking therapies. See also cognitive behavioural therapies
accessed by ethnic minorities, 304
aims of, 420
for alcohol use problems, 257
in case studies, 159
for common mental health problems, 25
consumerism and, 26–27, 31–32
costs of, 33
counselling in, 426–427
for depression, 159
patients’ preferences for, 46, 49–50 box, 403, 405
patients’ trust gained by, 115
for prisoners/offenders, 348
as psychological therapy basis, 420
Tang, Eugene, ix–x, 153, 172 box 11.8
Tanzania, 61
teaching and learning about mental health
overview, 439–456
attitude problems in, 447, 456 box
Balint groups in, 453
barriers against change in, 455
Cambridge–Calgary model for, 451
communication and interview skills
requirements in, 447, 449–450 box 30.2
in community vs. institutional settings, 439
core GP competencies for, 439–446,
440 box 30.1–445 box 30.1
current developmental stages for, 439
curriculum for, 439
depression management in, 449–450 box 30.2
digital recordings/DVDs in, 450, 451–453
effectiveness of, 455–456
evaluation of, 453, 454
feedback (audio-visual) in, 451, 452, 454
Gotland study in, 453
for GPs, 439
GP's vs. specialists' interests in, 447, 456
key points of, 456
knowledge and skills requirements in, 448
knowledge gaps in, 446–447, 456
in LAMI countries, 439, 454, 455
mental health education in PCMH, 439–446
problem-based interviewing in, 451, 452, 454
psychosocial interventions in, 446
QOF applied to, 6
quality of care improved and, 453–455
RCGP curriculum for, 439, 446
recommendations for, 455–456
role playing in, 450–451, 456
skill development in, 447–453
skills modelling in, 450
skills required for, 447, 449–450
skill-teaching methods, 450–453
SMI research in, 454–455
specialists' vs. PCMH GPs' interests in, 447, 456
telephone-based therapy and support
access to mental health and, 379, 387, 391, 394–395
in case study, 179, 12.2
in collaborative care, 404, 412–413
as developing modalities, 97
for ethnic minorities, 314
IAPT services using, 390–391
in nurse-led interventions, 379
for postnatal depression, 191
in suicide prevention safety plans, 117
Thomas, Laura, ix–x, 12, 21
for tobacco use disorders. See smoking
treatment decisions overview, 473–478
antidepressant medication in, 473–474, 476, 479
in case studies, 473–475, 476–477, 478
on depression, 473–475, 476–477, 478
 guideline recommendations for, 473–475
key points of, 479
physical health considerations in, 474–475, 479
the PICO approach in, 479, 476–478, 479
for primary- vs. secondary-care patients, 474, 475, 479
research needed for, 478
trial evidence application in, 475–478
tuberculosis, 57, 58, 278
Turkey, 182, 21
Tylee, Andre, ix–x, 87–98
United Nations Development Programme (UNDP), 56
United States access to mental health care for ethnic minorities in, 305
alcohol use problem screening in, 254
the American bypass to psychiatric care, 14
antidepressants prescribed for young people in, 33
behavioural health service care in, 7
collaborative care in, 179, 403–404
DART programme in, 285
dyslipidaemia in, 281
early psychosis intervention in, 216–217
health expenditure in, 605
health insurance coverage in, 217–218
HMO system in, 14
migrants' ethnicities in, 300
National Comorbidity Survey of, 14
neuropsychiatric disorders and, 97
nurse training in, 377–378
PCMH in, 6
psychiatric disorder prevalence in, 182
search back from, 179
self-help therapies in, 48
stepped care formulated in, 403
stepped care trials in, 408
Veteran Administration and SMI care, 406
universal health coverage (UHC), 7, 58, 59, 361
van Beljouw, M., 411
Waheed, Waquas, ix
Wales, 7, 294, 343, 345
Watts, C. A. H. and B., 1
Wessex Research Network (WReN), 467, 468
World Health Organization women. See also child mortality; maternal health issues; nurses; perinatal mental health problems
alcohol intake guidelines considerations in, 32
alcohol use problems in, 251
AMP psychosocial intervention for, 390
anxiety rates among, 16, 125
anxiety screening in, 127
as asylum seekers/refugees, 313, 316, 317–318, 319
depression rates among, 16, 29–30, 40–41
eating disorders among, 268–269
eating disorders in, 268–269, 273–274
women (cont.)
family/social connections of
as advantages to, 28
help-seeking responses in, 73
life expectancy reduced by
mental disorders, 89–90
osteoporosis in, 291
overrepresentation of, in
PCMH, 27–28
as prisoners/offenders,
343–344, 349
psychological therapies used
by, 386
self-harming rates among, 16
sexual problems as defined
by, 327
sexual problems in, 329/23.1,
329, 330, 331, 332,
336–337, 339
Strong-Black-Woman self-
image, 29–30
suicide in, 103,
231–232/16.2, 231, 484
suicide-related PCMH
sought by, 106
weight changes in, 289
World Bank, 16–17, 55, 565.1,
58
World Health
Organization (WHO)
Collaborative Study of
Psychological Problems in
General Healthcare, 74–75
Commission on
Macroeconomics and
Health, 58
Commission on Social
Determinants of Health,
58
Depression treatments
developed by, 97
Disability Assessment
Schedule, 81
on mental health, 2
Mental Health Expert
Committee of the World
Health Organization, 54
mental health training
programmes established
by, 61
mhGAP of, 54, 62, 64, 79, 81
on PCMH, 2
Strategies for Extending
Mental Health Care
programme, 61
World Mental Health
Surveys, 14, 20, 110–111
years lived with a disability
(YLDs), 89–90, 353, 373,
401. See also burdens of
specific mental disorders
young people. See also
child and adolescent
mental health
problems
access to mental health care
for, 390
cannabis use in, 215, 243
diabetes in, 286
eating disorders among,
268–269, 270
eating disorders in,
273–274
help-seeking for sexual
problems, 327
mortality in, 57, 58, 278